102460.KO Reyon Pharmaceutical Co Ltd
- Market cap
- KRW 171B
- P/E
- -
- P/B
- 0.88x
- ROE
- -18.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 102460.KO undervalued?
Graham numberThe Graham number of Reyon Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Reyon Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Reyon Pharmaceutical Co Ltd yet.
Reyon Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hem…
Full company profileReyon Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Reyon Pharmaceutical Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 122B | 126B | 123B | 132B | 130B | 143B | 154B | 151B | 148B | 146B | 144B |
| Gross Profit | 70.3B | 72.7B | 68.5B | 74.3B | 72.6B | 79.4B | 81.7B | 78.9B | 72.8B | 38.2B | 38.1B |
| Operating Income | 14.1B | 16.0B | 2.46B | 7.90B | 3.45B | 3.05B | 9.32B | 3.08B | -555M | -30.7B | -27.3B |
| EBITDA | - | 18.7B | 3.25B | 12.0B | 9.11B | 10.6B | 11.5B | 9.01B | 12.8B | 20.4B | 7.53B |
| Net Income | 10.7B | 12.9B | 1.34B | 5.94B | 3.84B | 5.54B | 7.43B | 3.58B | 4.15B | -29.6B | -35.1B |
| EPS | - | 753 | 80 | 352 | 222 | 312 | 419 | 195 | 226 | -1,616 | -1,913 |
| Balance Sheet | |||||||||||
| Total Assets | 210B | 291B | 303B | 274B | 318B | 478B | 485B | 500B | 500B | 465B | 444B |
| Total Liabilities | 30.4B | 71.2B | 77.8B | 52.2B | 87.5B | 233B | 237B | 251B | 250B | 245B | 250B |
| Shareholders' Equity | 179B | 220B | 224B | 220B | 230B | 245B | 248B | 249B | 250B | 220B | 195B |
| Cash & Short-term Investments | 1.55B | 530M | 8.78B | 5.83B | 12.2B | 66.7B | 16.0B | 24.1B | 10.2B | 6.67B | 7.02B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 9.47B | 16.8B | 11.4B | -12.2B | 4.60B | 11.7B | 8.73B | 8.65B | -1.44B | 1.46B | 13.0B |
| Capital Expenditure | 3.21B | 4.14B | 39.2B | 50.9B | 52.3B | 117B | 63.1B | 28.9B | 16.0B | 7.92B | 4.15B |
| Free Cash Flow | - | 12.1B | -28.0B | -63.6B | -47.7B | -105B | -54.4B | -20.2B | -17.5B | -6.46B | 8.85B |
| Ratios | |||||||||||
| ROE | 6.0% | 5.9% | 0.6% | 2.7% | 1.7% | 2.3% | 3.0% | 1.4% | 1.7% | -13.5% | -18.0% |
| ROA | 5.1% | 4.4% | 0.4% | 2.2% | 1.2% | 1.2% | 1.5% | 0.7% | 0.8% | -6.4% | -7.9% |
| Net Profit Margin | 8.8% | 10.2% | 1.1% | 4.5% | 3.0% | 3.9% | 4.8% | 2.4% | 2.8% | -20.3% | -24.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Reyon Pharmaceutical Co Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 27, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | KRW 2.75B | 150 | 66.3% |
| 2023 | KRW 2.74B | 149 | 76.4% |
| 2022 | KRW 4.56B | 257 | 61.4% |
| 2021 | KRW 3.46B | 195 | 62.6% |
| 2020 | KRW 5.78B | 334 | 150.5% |
| 2019 | KRW 8.26B | 490 | 139.1% |
| 2018 | KRW 5.87B | 348 | 437.0% |
| 2017 | KRW 4.52B | 264 | 35.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.02:1 on Dec 29, 2020.
Who owns Reyon Pharmaceutical Co Ltd
- Insiders 53.84%
- Institutions 0.43%
- Public & others 45.73%
- Shares outstanding 18.3M
- Free float 3.06M
Reyon Pharmaceutical Co Ltd company profile
- Company name
- Reyon Pharmaceutical Co Ltd
- Ticker
- 102460.KO
- ISIN
- KR7102460003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 461
- Fiscal year end
- December
- Address
- Building A, Mirae Asset Tower, Seoul, South Korea
- Phone
- 82 2 793 5557
- Website
- reyonpharm.co.kr
About Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study. In addition, the company engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases; and RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
Reyon Pharmaceutical Co Ltd management
3- Ms. Soon-Ock JungChairman & CEO · born 1950
- Yong-Hwan YooPresident, CEO & Representative Director · born 1974
- Hung-Muk ChoiExecutive Director